In Segment A, individuals will get distinctive doses and schedules of oral ABBV-744 tablet to detect Protected dosing regimen. More participants is going to be enrolled within the recognized monotherapy dosign routine. In Section B, members will get oral ruxolitinib and ABBV-744 will be given as "incorporate-on" therapy. In Section https://hectorcrdoa.jts-blog.com/31212325/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc